Pharmaceuticals News and Research

RSS

Provista, ARMSRx form partnership to provide pharmacy benefit services

Provista, LLC announced today that it has partnered with Administered Risk Management Services Rx, LLC (ARMSRx), a pharmacy benefit consulting firm that specializes in delivering superior results and ongoing support to the administration and management of prescription drug benefit programs and afford Provista members with the highest-quality pharmaceutical care at the lowest possible cost.

13 Apr 2010

Mersana Therapeutics, Teva Pharmaceutical Industries sign research and license agreement

Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has entered into a research and exclusive license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize XMT-1107, a novel fumagillin analog, for the treatment of all indications, including cancer.

13 Apr 2010

NaviNet to discuss on the use and adoption of HIT at World Health Care Congress 2010

NaviNet, America's largest real-time healthcare communications network, today announced that Kim Labow, senior vice president and chief marketing officer, will participate in a panel discussion about innovative approaches to achieve meaningful use and adoption of health information technology.

13 Apr 2010

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research, April 17 – 21, 2010, in Washington, DC.

13 Apr 2010

AVEO Pharmaceuticals to present preclinical data from translational research platform at AACR 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that preclinical data from its translational research platform and antibody pipeline will be presented during six poster sessions at the American Association for Cancer Research 101st Annual Meeting 2010 being held April 17-21, 2010, in Washington, D.C.

13 Apr 2010

Investment report on Rexahn Pharmaceuticals

StockPreacher.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

13 Apr 2010

Health care professionals urge Congress to support nation's chemical regulatory reform

On the eve of legislation slated to be introduced this month to reform the Toxic Substances Control Act, almost two dozen organizations representing health care professionals, along with health sector businesses sent letters to Congress urging the passage of strong reform of our nation's chemical regulatory system.

13 Apr 2010

TD2, Horizon Discovery announce strategic alliance to advance personalized medicine

A strategic alliance announced today between TGen Drug Development (TD2) and Horizon Discovery Limited will significant advance personalized medicine.

13 Apr 2010

Invida Group converges subsidiaries under unified global brand name

At an event marked by celebration and strategic insight, Invida Group officially ushered in a new era as the company converges its subsidiaries under a unified global brand name. Held at Invida's new corporate headquarters in Singapore's Science Park One, the event drew 180 participants.

13 Apr 2010

New website for PricewaterhouseCoopers' Health Industries practice

PricewaterhouseCoopers LLP today launched a new website for their Health Industries practice – www.pwc.com/healthreform – which will serve as a central point of access for PricewaterhouseCoopers' latest insight and analysis on the implications of health reform for health organizations including insurers, physicians, hospitals and other providers, pharmaceutical and life sciences companies and employers.

13 Apr 2010

NeoStem opens new adult stem cell collection center in Austin, TX

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced the launch of the newest adult stem cell collection center in its network to open in Austin, TX on April 15, 2010.

13 Apr 2010

Copaxone achieves one million patient years of experience in treatment of RRMS

Teva Pharmaceutical Industries, Ltd. announced today that Copaxone® (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA).

13 Apr 2010

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Myriad Pharmaceuticals, Inc today announced that it has received a notice from Javelin Pharmaceuticals, Inc. of its intent to terminate the merger agreement between the two companies.

13 Apr 2010

Tongjitang special committee to evaluate Hanmax Investment and Fosun Industrial buyout proposal

Tongjitang Chinese Medicines Company, a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it has established a special committee to evaluate the proposal presented on April 8, 2010 by Hanmax Investment Ltd. and Fosun Industrial Co., Ltd.

13 Apr 2010

San Diego Union-Tribune examines pharma's growing interest in neglected diseases

The San Diego Union-Tribune examines the pharmaceutical industry's growing interest in developing new treatments for what are known as "neglected diseases."

13 Apr 2010

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.

13 Apr 2010

RXi Pharmaceuticals, miRagen Therapeutics enter into research collaboration

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, and miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA -based therapeutics for cardiovascular and muscle disease, announced today that they have entered into a research collaboration.

13 Apr 2010

Decrease in manic symptoms severity influences prescribing decisions for bipolar mania

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists say that the decrease in severity of manic symptoms is the attribute that most influences their prescribing decisions in bipolar mania. Clinical data and the opinions of interviewed thought leaders indicate that Eli Lilly's Zyprexa (olanzapine) has advantages in this attribute over AstraZeneca/Astellas's Seroquel (quetiapine), the sales-leading agent in the bipolar disorder drug market.

13 Apr 2010

Pancreaze Delayed Release Capsules receive FDA approval

The U.S. Food and Drug Administration today approved Pancreaze Delayed Release Capsules, a pancreatic enzyme product. It is the third such product to receive FDA approval.

13 Apr 2010

RXi Pharmaceuticals, Mirna Therapeutics form microRNA research collaboration

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.

12 Apr 2010

Pharmaceuticals News and Research

Provista, ARMSRx form partnership to provide pharmacy benefit services

Mersana Therapeutics, Teva Pharmaceutical Industries sign research and license agreement

NaviNet to discuss on the use and adoption of HIT at World Health Care Congress 2010

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

AVEO Pharmaceuticals to present preclinical data from translational research platform at AACR 2010

Investment report on Rexahn Pharmaceuticals

Health care professionals urge Congress to support nation's chemical regulatory reform

TD2, Horizon Discovery announce strategic alliance to advance personalized medicine

Invida Group converges subsidiaries under unified global brand name

New website for PricewaterhouseCoopers' Health Industries practice

NeoStem opens new adult stem cell collection center in Austin, TX

Copaxone achieves one million patient years of experience in treatment of RRMS

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Tongjitang special committee to evaluate Hanmax Investment and Fosun Industrial buyout proposal

San Diego Union-Tribune examines pharma's growing interest in neglected diseases

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

RXi Pharmaceuticals, miRagen Therapeutics enter into research collaboration

Decrease in manic symptoms severity influences prescribing decisions for bipolar mania

Pancreaze Delayed Release Capsules receive FDA approval

RXi Pharmaceuticals, Mirna Therapeutics form microRNA research collaboration

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence